A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer

Inclusion Criteria: * adenocarcinoma of the prostate * life expectancy \> 3 months, * symptomatic from bone metastases * radiologic evidence of metastatic bone disease * stable level of pain control * \>18 years * ability to complete assessments * prior treatment (chemo) \> 4 weeks previous * discontinued anti-androgens for \> 4 weeks Exclusion Criteria: * prior strontium therapy * previous hemibody RT within 6 weeks * previous cytotoxic chemotherapy within 4 weeks * use of bisphosphonate medications within 4 weeks * change in steroid dose within 4 weeks * active uncontrolled infection * impending or present spinal cord compression * significant neurological disorder * impending pathological fracture * severe urinary incontinence